CI

At a glance

ClinicalIndex Comparison Record
Phase 4Completed· 102 enrolled
Drug / intervention
Liraglutide +1 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT03449654
NCT03449654Phase 4Completed
CompareCT.gov

Effect of Liraglutide on Vascular Inflammation in Type-2 Diabetes: A Randomized, Placebo-controlled, Double-blind, Parallel Clinical PET/CT Trial The Liraflame Trial

Steno Diabetes Center Copenhagen·interventional·Posted Feb 28, 2018·Updated Jun 11, 2020

In Brief

A Phase 4 clinical trial evaluating Liraglutide and Placebo (for liraglutide) for Diabetes Mellitus, Type 2. Completed, enrolled 102 participants across 1 site.

Detailed Summary

The objective of this study is to evaluate the mechanism behind the anti-atherogenic effects of liraglutide. In a randomized, placebo-controlled, double-blind, parallel trial we will included 100 patients with type 2 diabetes. Patients will be randomized 1:1 to an active treatment period of 26 weeks or placebo for 26 weeks. The primary endpoint is change from baseline to week 26 in vascular inflammation, assessed by Flour Deoxy Glucose (FDG)-Positron Emission Tomography/Computed Tomography (PET/CT)

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsDiabetes Mellitus, Type 2
CountriesDenmark
CollaboratorsRigshospitalet, Denmark

Timeline

Phase 4CompletedFinished
201820192020202120222023202420252026
First PostedFeb 28, 2018
Enrollment StartOct 26, 2017
Primary CompletionAug 16, 2019
TodayJul 2, 2026
Enrollment to primary: 1.8 yearsPosted 8.3 years ago

Interventions

Liraglutidedrug

Liraglutid

Placebo (for liraglutide)drug

Placebo (for liraglutide)